In the pharmaceutical industry, Mebeverine Hydrochloride is a specialized musculotropic antispasmodic. As a pharmacist and manufacturer, I view Mebeverine as a “targeted” gastrointestinal drug because it acts directly on the smooth muscles of the gut without affecting the normal motility of the bowel or causing the “anticholinergic” side effects (like dry mouth or blurred vision) typical of older antispasmodics.
Primary Clinical Uses
Irritable Bowel Syndrome (IBS): The primary indication for the symptomatic relief of abdominal pain, cramps, persistent diarrhea, and flatulence associated with IBS.
Gastrointestinal Spasm: Used to treat spasms of the GI tract secondary to organic diseases like diverticulitis or regional enteritis.
Chronic Irritable Colon: Management of functional bowel disorders characterized by irregular bowel movements and pain.
Mechanism of Action: Direct Muscle Relaxation
Mebeverine works through a non-atropine-like mechanism, focusing specifically on the smooth muscle cells of the colon.
Ion Channel Modulation: It acts directly on the smooth muscle cells by inhibiting voltage-gated sodium channels and limiting the replenishment of intracellular calcium stores.
Spasmolysis: By preventing the influx of sodium and the release of calcium, it stops the muscle from over-contracting (spasming).
Preserved Motility: Crucially, it does not interfere with the normal “peristalsis” (the wave-like movement that pushes food through), making it much more comfortable for long-term use than other antispasmodics.
The Manufacturer’s Perspective: Formulation & Export
From a production and global trade standpoint, Mebeverine is a high-demand product in the gastroenterology sector:
Sustained Release (SR) vs. IR: While the standard dose is 135 mg (Immediate Release), we often manufacture 200 mg SR Capsules. For your B2B marketplace, the 200 mg SR version is highly popular as it improves patient compliance to twice-daily dosing.
Stability & Coating: Mebeverine is stable but requires protection from humidity. At our WHO-GMP facility, we utilize film-coating for tablets to mask the bitter taste and Alu-Alu blister packaging to ensure a 36-month shelf life for export to Zone IVb regions.
Regulatory Compliance: We provide full CTD/eCTD Dossiers and bioequivalence data against the innovator (Colofac) to support registration in international markets.
Market Positioning: On your digital platforms, you can market this as a “Superior GI Antispasmodic” due to its lack of systemic side effects, which is a significant USP for B2B buyers.